OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Neurology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Issue Information	270
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome	134
Comorbidity patterns in people with multiple sclerosis: A latent class analysis of the Australian Multiple Sclerosis Longitudinal Study	129
COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition	101
Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis	91
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study	91
Lessons from the past to understand the future	90
	87
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study	86
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients	84
The effect of influenza vaccination on the rate of dementia amongst older adults	84
The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency	82
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage	80
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift	78
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy	65
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life	65
Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors	60
Central nervous system crystal‐storing histiocytosis: A case report and literature review	56
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study	56
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study	55
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease	55
The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective	54
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy	54
Prioritization process for European Academy of Neurology clinical practice guidelines	53
The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications	53

Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study	52
Diagnostic accuracy of nerve excitability and compound muscle action potential scan derived biomarkers in amyotrophic lateral sclerosis	51
Risk factors, neuroimaging correlates and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment	48
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report	46
Mirror therapy for unilateral neglect after stroke: A systematic review	45
Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta‐analysis of randomized controlled trials	45
Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis	45
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study	44
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment	43
Comparative features and outcomes of major neurological complications of COVID‐19	42
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities	41
Immunity and Gilles de la Tourette syndrome: A systematic review and meta‐analysis of evidence for immune implications in Tourette syndrome	41
Long‐term MRI changes in a patient with Kelch‐like protein 11‐associated paraneoplastic neurological syndrome	40
Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms	40
Neurovascular Involvement in Fibromuscular Dysplasia: A Clue for Reappraisal of Old Classifications	39
Plasma neurofilament light chain levels predict improvement in late phase after stroke	39